Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.

Mortality risk from PDAC surgery high in older adults

15 Nov 2019

Older adults suffer from excess mortality risk from surgical resection for pancreatic ductal adenocarcinoma (PDAC), a recent study has shown.

Researchers conducted a retrospective analysis of 6,149 PDAC patients (mean age, 64.9±12.3 years; 50.4 percent male) who were hospitalized for pancreaticoduodenectomy. More than a fifth (21 percent) were at least 76 years of age. Two-hundred participants died, yielding a 30-day in-hospital mortality rate of 3.25 percent.

Stratifying according to age showed that the mean length of hospital stay was significantly longer in those who were >76 years of age than in their younger counterparts (14.5±10.9 vs 13.1±10.4 days; p<0.001). Patients stayed in the hospital for a mean of 13±11 days overall.

Multivariable analysis confirmed that age was significantly associated with a prolonged stay in the hospital (rate ratio [RR], 1.09, 95 percent confidence interval [CI], 1.04–1.14; p<0.001). The same was true for being male (RR, 1.08, 95 percent CI, 1.04–1.12; p<0.001) and having a history of prior illness (RR, 1.35, 95 percent CI, 1.29–1.41; p<0.001).

Similarly, 30-day in-hospital mortality rates were greater for patients >76 years of age (4.11 percent vs 2.77 percent). The corresponding rate in the overall cohort was 3.24 percent. This was likewise confirmed in multivariate analysis (odds ratio, 1.46, 95 percent CI, 1.07–2.00; p=0.016).

Though the present study is the largest of its kind examining mortality rates in older adults undergoing resection for PDAC, future studies are still required to better determine which of the elderly population derive the most benefit from pancreaticoduodenectomy, the researchers noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.